Real-world data supports Opdivo plus Yervoy efficacy for advanced renal cell carcinoma, mirroring clinical trial results.

During a Case-Based Roundtable® event, Daniel J. George, MD, discusses how often community oncology participants see patients ...

Insurance firms in South Korea shift focus to guaranteed products for stable profits Insurers in South Korea prioritize ...

GI-102 is under clinical development by GI Innovation and currently in Phase II for Solid Tumor. According to GlobalData, Phase II drugs for Solid Tumor have a 37% phase transition success rate (PTSR) ...

In an extremely rare case, an unnamed 69-year-old man who had cirrhosis and liver cancer underwent a liver transplant and ...

Welcome to Fierce Pharma's regulatory tracker for the first half of 2025. | In this tracker, Fierce Pharma is recording the ...

Colorectal cancer (CRC) is the third most common cancer and the second most common cause of cancer deaths worldwide. In 2023, ...

In an extremely rare case, a doctor operating on a cancer patient in Germany accidentally 'transplanted' the disease into ...

The new year brings renewed hope for the parents of an eight-year-old Franksville boy who learned in 2024 his kidneys are failing and he's going to need a transplant. A ...

China NMPA approves Astellas Pharma’s Padcev in combination with Keytruda to treat advanced bladder cancer: Tokyo Thursday, January 9, 2025, 09:00 Hrs [IST] Astellas Pharma Inc.

As we age, our bodies undergo various physiological changes that necessitate a proactive approach to health management.

The safety profile of ICI for the treatment of malignancies in patients diagnosed with autoimmune and cholestatic liver disease (AILD ... esophageal cancer (n=1), small cell lung cancer (n=1), renal ...